Is Zymeworks Inc. (ZYME) a Buy, Sell, or Hold?
Zymeworks Inc.
NASDAQ:ZYME
$24.66 USD
-$0.28 (-1.12%)
- Volume
- 345.95K
- Average Volume
- 673.72K
- Market Capitalization
- $1.81B
- P/E Ratio
- -18.01
- Dividend Yield
- 0.00%
- Price Target
- $41.50
- Year High
- $29.75
- Year Low
- $11.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.82
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kenneth H. Galbraith |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ZYME |
| CUSIP | 98985Y108 |
| CIK | 0001937653 |
| Web | https://www.zymeworks.com |
| Phone | 16046781388 |
| Currency | USD |
| Employees | 264 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.82 |
| Quick Ratio | 10.82 |
| Cash Ratio | 6.85 |
Sales & Book Value
| Annual Sales | $105.96M |
| Price / Sales | 22.33 |
| Cash Flow | -1.03 |
| Price / Cash Flow | -23.59 |
| Price / Book | 11.26 |
Price Target and Rating
| Average Stock Price Forecast | $41.50 |
| High Stock Price Forecast | $48.00 |
| Low Stock Price Forecast | $31.00 |
| Forecast Upside/Downside | -40.58% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.08 |
| Trailing P/E Ratio | -18.01 |
| PEG Ratio | 0.90 |
| P/E Growth | 0.90 |
| Net Income | $-81.13M |
| Net Margin | -126.33% |
| Pretax Margin | -127.94% |
| Return on Equity | -37.79% |
| Return on Assets | -21.47% |
Financials Score
| AltmanZ Score | 0.68 |
| Piotroski Score | 4.00 |
| Working Capital | 350.03M |
| Total Assets | 478.22M |
| Ebit | -104.66M |
| Market Cap | 1.83B |
| Total Liabilities | 314.63M |
Poll Results
About Zymeworks Inc. (NASDAQ:ZYME) Stock
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly an ... d Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
2026-07-01 08:30:50
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
Theravance Stock Down 3% After Zymeworks Announces Buyout
2026-06-30 09:55:43
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
2026-06-29 15:32:12
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
2026-06-29 09:20:49
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
Zymeworks strikes $929 million deal for Theravance Biopharma
2026-06-29 06:13:26
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Zymeworks to Acquire Theravance Biopharma, Inc.
2026-06-29 06:00:00
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference ® in people's lives. This proposed acquisition adds YUPELRI®, the first and only nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), to Zymeworks' partnered portfolio, furthering the Company's commitment to improving outcomes for patients with serious diseases.
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
2026-06-18 08:00:00
Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery. VANCOUVER, BC, June 18, 2026 /PRNewswire/ - Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.
2026-06-14 18:05:00
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78. 6% in FRα-positive (≥75% at PS2) platinum-resistant ovarian cancer patients and 47. 4% in FRα-negative patients (<75% at PS2) across all dose levels studied Median duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.
Frequently Asked Questions
-
What is the current Zymeworks Inc. (ZYME) stock price?
-
Zymeworks Inc.(NASDAQ:ZYME) stock price is $24.66 in the last trading session. During the trading session, ZYME stock reached the peak price of $29.75 while $11.51 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was --1.12% while the dollar amount for the price change in ZYME stock was -$-0.28.
-
ZYME's industry and sector of operation?
-
The NASDAQ listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ZYME?
-
Thomas Spreter Von Kreudenstein | Director of Protein Engineering
Lindsey Foulkes | Senior Vice President of Corporate Development & Strategy
Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President
Shrinal Inamdar | Vice President of Investor Relations
Nina Weisser | Director of Multispecific Antibody Therapeutics -
How many employees does ZYME have?
-
Number of ZYME employees currently stands at 264. ZYME operates from 108 Patriot Drive, Middletown, BC 19709, US.
-
Link for ZYME official website?
-
Official Website of ZYME is: https://www.zymeworks.com
-
How do I contact ZYME?
-
ZYME could be contacted at phone #16046781388 and can also be accessed through its website. ZYME operates from 108 Patriot Drive, Middletown, BC 19709, US.
-
How many shares of ZYME are traded daily?
-
The average number of ZYME shares traded daily for last 3 months was 673.72K.
-
What is the market cap of ZYME currently?
-
The market value of ZYME currently stands at $1.81B with its latest stock price at $24.66